Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
Sep 21, 2023
LunAIRo Compares AD109 to Placebo Over 6 and 12 Months
Sep 18, 2023
Dr. Yee will lead Apnimed’s efforts to engage and inform the clinical community about Apnimed’s lead drug candidate AD109.
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
Sep 6, 2023
A post-hoc analysis of data from the MARIPOSA Phase 2b trial will be featured at a poster presentation.
Aug 30, 2023
Citi 18th Annual BioPharma Conference, Baird Global 2023 Healthcare Conference, and 2023 Cantor Fitzgerald Global Healthcare Conference
Aug 27, 2023
The selection is a recognition given to the industry’s most innovative and promising biotechnology companies who are pushing the boundaries in the clinic and beyond.
Aug 1, 2023
Fireside Chat: Wednesday, August 9, 2023
Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
Jul 12, 2023
Tuesday, July 18, 2023 at 8 a.m. ET.
May 23, 2023
June 5-8, 2023 at the Boston Convention & Exhibit Center
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
May 21, 2023
New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved
Both Objective and Subjective Outcomes in OSA Patients
Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023
May 15, 2023
– New MARIPOSA Data Showing AD109 Had Statistically Significant Improvement in Both Objective and Subjective Outcomes to Be Featured as an Oral Presentation in the Breaking News in OSA: New Approaches and New Trials Mini Symposium – Data Supporting Use of Specific...